According to Regulus Therapeutics's latest financial reports the company's total assets are $37.74 M. A companyโs total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Year | Total assets | Change |
---|---|---|
2022-12-31 | $46.71 M | -31.76% |
2021-12-31 | $68.45 M | 82.04% |
2020-12-31 | $37.6 M | -10.64% |
2019-12-31 | $42.08 M | 50.68% |
2018-12-31 | $27.92 M | -64.11% |
2017-12-31 | $77.8 M | -22.7% |
2016-12-31 | $0.10 B | -28.65% |
2015-12-31 | $0.14 B | -17.73% |
2014-12-31 | $0.17 B | 39.34% |
2013-12-31 | $0.12 B | 18.88% |
2012-12-31 | $0.10 B | 141.41% |
2011-12-31 | $42.88 M |
Company | Total assets | differencediff. | Country |
---|---|---|---|
Sanofi SNY | $139.81 B | 370,302.95% | ๐ซ๐ท France |
Biogen BIIB | $26.84 B | 71,017.70% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $95.15 B | 251,996.86% | ๐บ๐ธ USA |
AstraZeneca AZN | $101.11 B | 267,786.19% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $75.11 B | 198,891.71% | ๐ฌ๐ง UK |
Sangamo Therapeutics
SGMO | $0.16 B | 337.97% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | N/A | N/A | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $3.82 B | 10,046.18% | ๐บ๐ธ USA |